Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multistakeholder approach to innovations in NAFLD care.
Schattenberg JM, Allen AM, Jarvis H, Zelber-Sagi S, Cusi K, Dillon JF, Caussy C, Francque SM, Younossi Z, Alkhouri N, Lazarus JV. Schattenberg JM, et al. Among authors: younossi z. Commun Med (Lond). 2023 Jan 3;3(1):1. doi: 10.1038/s43856-022-00228-y. Commun Med (Lond). 2023. PMID: 36596859 Free PMC article.
Securing sustainable funding for viral hepatitis elimination plans.
Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Hatzakis A, et al. Among authors: younossi z. Liver Int. 2020 Feb;40(2):260-270. doi: 10.1111/liv.14282. Epub 2019 Dec 5. Liver Int. 2020. PMID: 31808281 Review.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Taylor RS, et al. Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4. Gastroenterology. 2020. PMID: 32027911 Free article.
The times they are a-changin' (for NAFLD as well).
Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. Ratziu V, et al. Among authors: younossi z. J Hepatol. 2020 Dec;73(6):1307-1309. doi: 10.1016/j.jhep.2020.08.028. Epub 2020 Sep 2. J Hepatol. 2020. PMID: 32890593 No abstract available.
Defining comprehensive models of care for NAFLD.
Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Lazarus JV, et al. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):717-729. doi: 10.1038/s41575-021-00477-7. Epub 2021 Jun 25. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34172937 Review.
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators. Younossi ZM, et al. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2050-2058.e12. doi: 10.1016/j.cgh.2021.07.020. Epub 2021 Jul 15. Clin Gastroenterol Hepatol. 2022. PMID: 34274514 Free article. Clinical Trial.
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM, Stepanova M, Noureddin M, Kowdley KV, Strasser SI, Kohli A, Ruane P, Shiffman ML, Sheikh A, Gunn N, Caldwell SH, Huss RS, Myers RP, Wai-Sun Wong V, Alkhouri N, Goodman Z, Loomba R. Younossi ZM, et al. Hepatol Commun. 2021 May 12;5(7):1201-1211. doi: 10.1002/hep4.1710. eCollection 2021 Jul. Hepatol Commun. 2021. PMID: 34278169 Free PMC article.
Advancing the global public health agenda for NAFLD: a consensus statement.
Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Lazarus JV, et al. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27. Nat Rev Gastroenterol Hepatol. 2022. PMID: 34707258 Free article. Review.
739 results